Saturday, August 20, 2022 1:26:51 PM
You are referring to the post below that has historical fact and links to back it up.
Your post is totally unsupported.
Neurotrope is a front for old money and connected folk. They are trying to commercialize a very OLD drug that has not been taken forward because it needs to be synthesized as the natural version is too rare. Most, if not all of the research on this drug has been paid for by the U.S. government.
Three years ago I stated my discomfort with the way this company came into being and was run:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=128690545
Shortly after this was posted the Pump and Dump I prophesied was realized and a great deal of retail money was taken out of the U.S. market, minimizing the risk of the founding stockholders.
Retail will continue to get the short end of the stick here to the bitter end. I will not invest in this company because I know how it ends... If the science is not successful the company goes broke and retail will be the bagholder. If it is successful read to the end of this post to find the outcome.
This drug is owned by old money "non profit" institutions. These are the two most prominent in the story:
Rockefeller Neuroscience Institute
https://directory.hsc.wvu.edu/Department/2192
Woods Hole Oceanographic Institution
www.whoi.edu
The initial investors have been selling stock to recoup their initial cost of funding the company on price spikes and replenishing it with warrants.
I am not convinced that treating Alzheimer's is the primary goal of Neurotrope. It is also not clear that people who buy stock in NTRP will be the primary beneficiaries if the company is successful. I suspect it will be the founding stockholders who have probably already made most of their "investment" back by selling at higher prices.
I am also not sure if there is solid protection for the IP as with proof of concept someone might design a new synthetic chemical that could do it all better. They have patents but I don't know how enforceable they would be against a newly designed chemical.
This paragraph is updated from the previous sticky:
I think Anavex may draw the ire of NTRP proponents because 2-73 creates cellular homeostasis which is both neuroprotective and allows neurogenesis to take place. Blarcamesine or 2-73 is in trials for Alzheimer's, Parkinson's dementia, and is both neuroprotective and restorative. It is more economical than bryostatin could ever be and may get provisional approval from the Australian TGA within a year.
... and then there's 3-71.
Recent TAOX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:02:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:01:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:01:11 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 09:21:40 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/02/2026 09:32:45 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/02/2026 09:30:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 09:23:07 PM
- TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation • PR Newswire (US) • 11/18/2025 02:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/12/2025 09:10:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/07/2025 09:41:16 PM
- TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds • PR Newswire (US) • 11/04/2025 02:15:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/24/2025 08:12:47 PM
- TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency • PR Newswire (US) • 10/20/2025 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/17/2025 09:13:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 10:12:21 AM
- TAO Synergies Announces $11 Million Private Placement • PR Newswire (US) • 10/13/2025 09:09:00 PM
- TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO) • PR Newswire (US) • 09/22/2025 01:15:00 PM
- TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event • PR Newswire (US) • 09/08/2025 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2025 09:00:44 PM
- TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy • PR Newswire (US) • 08/26/2025 01:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2025 08:51:57 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/14/2025 08:50:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 08:19:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 09:17:38 PM
